Navigation Links
Hyaluronic Acid Dermal Filler Market Skyrockets
Date:2/20/2008

The US dermal filler market is expected to grow at a compound annual growth

rate of 20% from 2006-2011, according to Millennium Research Group

WALTHAM, Mass., Feb. 20 /PRNewswire/ -- According to Millennium Research Group's Global Markets for Hyaluronic Acid in Aesthetic, Orthopedic, and Emerging Applications 2008 report, the US hyaluronic acid (HA) dermal filler market will grow at a compound annual growth rate of nearly 20% from 2006 through 2011.

Growth in this market will be driven by a rising demand for dermal filler procedures, performed primarily to correct facial blemishes, and a global population increasingly interested in cosmetic enhancement. HA dermal fillers, the second-most popular facial aesthetic treatment after botulinum toxin (Botox) injections in 2006, will experience very strong growth over the next five years because cosmetic HA injections are quick, safe, effective, and relatively inexpensive.

"Since HA is a naturally occurring compound, many patients are comfortable receiving cosmetic treatments using this product," says Jaya Classen, Senior Analyst at Millennium Research Group. "As a result, it is expected that HA dermal fillers will further penetrate the market at the expense of competing treatments, such as collagen and particle and polymer filler injections."

The Global Markets for Hyaluronic Acid in Aesthetic, Orthopedic, and Emerging Applications 2008 report includes coverage of the HA dermal filler and viscosupplementation markets in the US, Europe (France, Germany, Italy, and the UK), and Asia Pacific (Japan, China, South Korea, and Taiwan). The report provides coverage of all key industry competitors, including Allergan, Fidia Farmaceutici, Genzyme Biosurgery, Medicis Pharmaceuticals, Seikagaku Corporation, and Q-Med.

About Hyaluronic Acid

HA is a compound that is found in human connective tissue. Its degradation in deep and superficial dermal layers has been implicated in the overt
'/>"/>

SOURCE Millennium Research Group
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. 1st EMEA application filed for product using innovative intradermal microinjection system BD Soluvia
2. PriCara(TM) Recalls 25 mcg/hr DURAGESIC(R) (fentanyl transdermal system) CII Pain Patches
3. New Study Provides Scientific Evidence That DermaLastyl Face Cream Reduces Wrinkles
4. Building an Effective Sales Force to Serve the U.S. Hospital Market
5. Greenway Medical Technologies Broadens Sales Efforts With Entrance Into Federally Qualified Health Center Marketplace
6. Spectragenics Names Rpr Marketing Communications Agency of Record
7. Northfield Automation Announces Wholly Owned Subsidiary to Diversify Into Medical Device Market
8. Nano Pet Products, LLC Named Exclusive Worldwide Licensee by Schoeller(R) Technologies AG for Pet Products to Develop the Most Technologically Advanced Pet Brands on the Market Today
9. Darwin Enters into Marketing Partnership with Agency Specialty Product Network
10. Healthy Coffee International, Inc. Establishes Healthy Coffee USA, Inc. as Its Marketing Arm
11. A Favorite in France, Elgydium(R) Toothpaste Makes Entrance Into the U.S. Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2008)... Conn., July 24 /PRNewswire/ -- People think it,s ...ffer many opportunities to eat right,and stay fit....t menu,selections, so if you order carefully your ...o: http://www.newscom.com/cgi-bin/prnh/20071212/N...mptation, you,ll want to stay,away from the cruise...
(Date:7/24/2008)... Greater access for people with disab...oad on ,Social Security disability system. , ...24, 2008 -- With the signing of the Americans with...n in the lives of people with disabilities and the... gained better access to methods that help them im...
(Date:7/24/2008)... A cleanroom manufacturing company ha...cleanrooms. The feature is a utility panel which ...hance the cleanroom appearance. , ...- Gerbig Engineering, a designer, fabricator and i...t they are now offering a utility panel for integr...
(Date:7/24/2008)... As America's baby boomers age, ...itions such as diabetes that necessitate the use o...t bracelet jewelry gives a generation attractive i...mation. , (PRWEB) July 24...tening health conditions can make a statement in m...
Breaking Medicine News(10 mins):Health News:Actress, Author Mariel Hemingway & Travelers Advantage Say: Treat Yourself To a Healthy Cruise 2Health News:Actress, Author Mariel Hemingway & Travelers Advantage Say: Treat Yourself To a Healthy Cruise 3Health News:Allsup Salutes 18th Anniversary of Americans with Disabilities Act 2Health News:Allsup Salutes 18th Anniversary of Americans with Disabilities Act 3Health News:Gerbig Engineering Announces Availability of Cleanroom Utility Panel 2Health News:Aging Baby Boomers Meld Life-saving Data and Style with Lauren's Hope Fashion Medical ID Bracelet 2Health News:Aging Baby Boomers Meld Life-saving Data and Style with Lauren's Hope Fashion Medical ID Bracelet 3
Life After Death: Organ Donation
...the first study to show that even mildly abnormal ...n elderly men undergoing major surgery," said Dr. ...dical Center and Brown University in Rhode Island....rovidence Veterans Affairs Medical Center and The ...
...s at the University of California, Riverside have ...nces, for two key proteins in the 'dragline silk' ...ad to a variety of new materials for industrial, m...dow spiders dragline silk is a standout compared t...
...-Hajam carefully placed the glass jars over the sl...n to pump out the air. In the ensuing vacuum , the... into the clear containers. "The Assyrians, the C... used to practice cupping to draw out the corrupt ...
Other Medicine News:Health News:Life After Death: Organ Donation 2Health News:Life After Death: Organ Donation 3Health News:Abnormality in the Red Blood Count Cell Poses High Risks 2Health News:Genetic Secrets Behind the Dragline Silk 2Health News:Ancient Healing Technique Gains New Popularity in Iraq 2
(Date:7/22/2008)... Two Regimens Including Lantus(R) and Apidra(R) R...nts with Type 2 Diabetes, Whatever the Algorithm ..., N.J., July 22 /- Results from the "... a Simple Algorithm to Carbohydrate,Counting for A...re,published in the American Diabetes Association,...
(Date:7/22/2008)...est Developed and Validated by Columbia University...s, Proprietary MicroRNA Technology, The Test Dif...ell Lung Cancer (NSCLC), Classifying Squamous-Cel... 96 Percent and Specificity of 90 Percent,This is ...RNAs, Sensitivity as Biomarkers for Accur...
(Date:7/22/2008)... A Pilot Study Suggests That Ekkyo,s New Approach ...tically Improve Scar Healing Physiology, MARSEILL...y known as,Heatwave Technology) a photomedicine co...ystems for skin scar prevention and reduction, ann...le in Lasers in Surgery and Medicine*,reporting th...
(Date:7/21/2008)... LONDON, July 21 /- The SEAS (Simva... investigated the effects of intensive,cholesterol...mg daily) and,ezetimibe (10 mg daily) in patients ...olves partial blockage of the aortic valve in,the ...people in Western,populations. Left untreated, it ...
Breaking Medicine Technology:Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 2Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 3Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 4First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 2First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 3First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 4First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 5Ekkyo Describes the First Benefits of Controlled Hyperthermia in Humans in "Lasers in Surgery and Medicine" 2Ekkyo Describes the First Benefits of Controlled Hyperthermia in Humans in "Lasers in Surgery and Medicine" 3Results From the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Study 2Results From the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Study 3Results From the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Study 4Clarient Reports First Quarter 2008 18095 1Clarient Reports First Quarter 2008 18095 2Clarient Reports First Quarter 2008 18095 3Clarient Reports First Quarter 2008 18095 4Clarient Reports First Quarter 2008 18095 5Clarient Reports First Quarter 2008 18095 6Clarient Reports First Quarter 2008 18095 7Clarient Reports First Quarter 2008 18095 8Patient Safety Authority Issues Annual Report for 2007 18091 1Patient Safety Authority Issues Annual Report for 2007 18091 2Patient Safety Authority Issues Annual Report for 2007 18091 3Patient Safety Authority Issues Annual Report for 2007 18091 4Patient Safety Authority Issues Annual Report for 2007 18091 5Patient Safety Authority Issues Annual Report for 2007 18091 6Patient Safety Authority Issues Annual Report for 2007 18091 7Patient Safety Authority Issues Annual Report for 2007 18091 8Patient Safety Authority Issues Annual Report for 2007 18091 9Patient Safety Authority Issues Annual Report for 2007 18091 10Patient Safety Authority Issues Annual Report for 2007 18091 11Patient Safety Authority Issues Annual Report for 2007 18091 12Patient Safety Authority Issues Annual Report for 2007 18091 13Patient Safety Authority Issues Annual Report for 2007 18091 14Patient Safety Authority Issues Annual Report for 2007 18091 15Patient Safety Authority Issues Annual Report for 2007 18091 16Patient Safety Authority Issues Annual Report for 2007 18091 17Patient Safety Authority Issues Annual Report for 2007 18091 18Sigma Aldrich Announces the Integration of Riedel De Haen Into Core Product Brands 5001 1Sigma Aldrich Announces the Integration of Riedel De Haen Into Core Product Brands 5001 2Sigma Aldrich Announces the Integration of Riedel De Haen Into Core Product Brands 5001 3Neurocrine Biosciences Reports First Quarter 2008 Results 1949 1Neurocrine Biosciences Reports First Quarter 2008 Results 1949 2Neurocrine Biosciences Reports First Quarter 2008 Results 1949 3Neurocrine Biosciences Reports First Quarter 2008 Results 1949 4Neurocrine Biosciences Reports First Quarter 2008 Results 1949 5Neurocrine Biosciences Reports First Quarter 2008 Results 1949 6Neurocrine Biosciences Reports First Quarter 2008 Results 1949 7Neurocrine Biosciences Reports First Quarter 2008 Results 1949 8
For the direct, colorimetric determination of calcium in human serum or urine. Linearity: 20 mg/dl.
Alanine Aminotransferase (ALT) reagent is used for the quantitative determination of alanine aminotransferase (Glutamate pyruvate transaminase, SGPT) in human serum.
For the quantitative determination of Alanine Aminotransferase in serum. Optimized IFCC without P-5'-P, Linearity: 500 IU/L at 37 C. Liquid Working Reagent prepared with simple 1:9 dilution.
For the determination of urea nitrogen in human serum.
Medicine Products: